Citrus oil may help relieve dry mouth symptoms caused by radiation therapy in head and neck cancer

Share This Post

According to a new study by Stanford University School of Medicine, a compound found in citrus oil may help relieve dry mouth symptoms caused by radiation therapy in head and neck cancer patients. The oil cells of citrus peel are rich in essential oils, about 0.5% to 2% of the fresh weight of the peel. The main ingredient of citrus essential oil is d-limonene (d-Limonene), and the main role for radioactive dry mouth is d-limonene.

This compound, called d-limonene, protects saliva cells of mice exposed to radiation therapy without weakening the effects of radiation on tumors. Researchers led by Julie Saiki have also shown that oral d-limonene can be transported to the salivary glands of the body. A series of experiments with mouse cells exposed to radiation showed that d-limonene reduced the concentration of aldehydes in adult and salivary stem and progenitor cells. Even when cells are treated for several weeks after radiation exposure, d-limonene can still improve its recovery ability, repair glandular structure and produce saliva. Mice receiving d-limonene and exposed to radiation also produced more saliva than mice not receiving d-limonene and exposed to radiation.

About 40% of head and neck cancer patients undergoing radiotherapy suffer from xerostomia, which is not only uncomfortable, but also makes it difficult for patients to speak and swallow, and it is more likely to suffer from mouth pain or tooth decay, and in some cases Can cause tooth loss. Moreover, although there may be some recovery in the first few years after treatment, once saliva becomes impaired, it will usually be affected for life. Subsequent research is ongoing, and if it works, the drug will be used safely to prevent dry mouth in the long-term and make it easier for patients to tolerate radiation therapy after treatment and improve the quality of life.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy for AIDS related B Cell malignancies
Aids cancer

CAR T Cell therapy for AIDS related B-Cell malignancies

CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient’s T cells to express chimeric antigen receptors (CARs) targeting CD19 on B cells. This treatment holds promise in eradicating malignant B cells but must carefully manage immunosuppression in HIV-positive individuals.

Cancer statistics in India 2024
Cancer

Cancer statistics in India 2024: Incidence, estimates and projections

In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most prevalent among women and men, respectively. Sadly, many cases are diagnosed late, impacting survival rates. Improved awareness and access to healthcare are crucial. By 2030, cancer incidence is expected to surpass 1.7 million cases annually. Efforts to enhance prevention, early detection, and treatment access are crucial to mitigate this growing burden. Check our cancer statistics in India for 2024 and future projections.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
Need help with cancer treatment?
Scan the code
Hello,
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy